Recombinant Human SUMO2 (N-6His)

Description

EnkiLife provides the Recombinant Human SUMO2 (N-6His) protein,aslo know as Small Ubiquitin-Related Modifier 2,SUMO-2,HSMT3,SMT3 homolog 2,SUMO-3,Sentrin-2,Ubiquitin-Like Protein SMT3A,Smt3A,SUMO2,SMT3A,SMT3H2, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Small Ubiquitin-Related Modifier 2 is produced by our E.coli expression system and the target gene encoding Met1-Gly93 is expressed with a 6His tag at the N-terminus.Accession:AAH08450.1. Expression Host:E.coli.Species:Human.Predicted Molecular Mass:13 KDa. Background:Small Ubiquitin-Related Modifier 2 (SUMO2) is an Ubiquitin-like protein that belongs to the ubiquitin family with SUMO subfamily. It is a family of small, related proteins that can be enzymatically attached to a target protein by a post-translational modification process termed sumoylation. SUMO2 can be covalently attached to proteins as a monomer or as a lysine-linked polymer. Covalent attachment via an isopeptidebond to its substrates requires prior activation by the E1 complex SAE1-SAE2 and linkage to the E2 enzyme UBE2I, and can be promoted by an E3 ligase such as PIAS1-4, RANBP2 or CBX4. This post-translational modification on lysine residues of proteins plays a crucial role in a number of cellular processes such as nuclear transport, DNA replication and repair, mitosis and signal transduction. Polymeric SUMO2 chains are also susceptible to polyubiquitination which functions as a signal for proteasomal degradation of modified proteins.